a Institute for Myeloma and Bone Cancer Research (IMBCR) , West Hollywood , CA , USA.
b University of Arizona College of Medicine - Tucson , Tucson , AZ , USA.
Expert Rev Mol Diagn. 2018 Apr;18(4):319-329. doi: 10.1080/14737159.2018.1448269. Epub 2018 Mar 7.
B-cell maturation antigen (BCMA) is a cell membrane bound tumor necrosis factor receptor family member that is expressed exclusively on late stage normal and malignant B-cells and plasma cells. Addition of two of its ligands, B-cell activating factor and a proliferation inducting ligand, to normal B-cells cause B-cell proliferation and antibody production. Serum BCMA is elevated among patients with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), and is a prognostic and monitoring tool for these patients. The first anti-BCMA antibody (Ab) was developed in 2007. Recently, biotech and pharmaceutical companies have created various forms of BCMA-directed Abs (naked Abs, Ab drug conjugates, and bispecific Abs) and cellular therapies (chimeric antigen receptor T-cells) with promising clinical results. Areas covered: This BCMA review encompasses full-text publications of original research articles and abstracts presented at hematology/oncology meetings. Expert commentary: The limited preclinical and ongoing clinical studies published to date evaluating BCMA-directed therapies have shown great promise. It has also been demonstrated that BCMA is solubilized and elevated in the blood of MM, Waldenstrom's macroglobulinemia and CLL patients, and is also responsible for the immune deficiency in MM. Reducing circulating levels may improve the efficacy of these treatments.
B 细胞成熟抗原（BCMA）是一种细胞膜结合的肿瘤坏死因子受体家族成员，仅在晚期正常和恶性 B 细胞和浆细胞上表达。将其两种配体，B 细胞激活因子和增殖诱导配体，添加到正常 B 细胞中会导致 B 细胞增殖和抗体产生。多发性骨髓瘤（MM）和慢性淋巴细胞白血病（CLL）患者的血清 BCMA 升高，是这些患者的预后和监测工具。第一种抗 BCMA 抗体（Ab）于 2007 年开发。最近，生物技术和制药公司已经创建了各种形式的 BCMA 导向 Ab（裸 Ab、Ab 药物偶联物和双特异性 Ab）和细胞疗法（嵌合抗原受体 T 细胞），具有有前途的临床结果。涵盖领域：本 BCMA 综述包括血液学/肿瘤学会议上发表的原始研究文章和摘要的全文出版物。专家评论：迄今为止，已发表的有限的临床前和正在进行的临床研究评估了 BCMA 导向的治疗方法，显示出巨大的潜力。已经证明，BCMA 在 MM、华氏巨球蛋白血症和 CLL 患者的血液中可溶解和升高，并且还负责 MM 中的免疫缺陷。降低循环水平可能会提高这些治疗的疗效。
